

Minutes of the 2026 Annual General Meeting of Shareholders Winnery Medical Public Company Limited

Date, Time, and Venue

The 2026 Annual General Meeting of Shareholders of Winnery Medical Public Company Limited (the “**Company**”) was convened on 30 April 2026, at 10.00 hrs. via electronic meeting lived from the Conference Room located at the Company’s head office No. 634/4, Soi Ramkhamhaeng 39 (Thepleela 1) Alley, Pracha Uthit Road, Wang Thonglang Sub-District, Wang Thonglang District, Bangkok 10310.

Directors present at the Meeting.

- | | |
|---------------------------------------|---|
| 1. Asst Prof Dr. Terdsak Rojsurakitti | Independent Director / Chairman of the Board of Directors / Chairman of the Good Corporate Governance and Sustainability Committee / Chairman of the Nomination and Remuneration Committee |
| 2. Mr. Chanat Sorakraikitikul | Independent Director / Chairman of the Audit Committee |
| 3. Dr. Renu Ubol | Independent Director /Member of the Audit Committee / Member of the Good Corporate Governance and Sustainability Committee / Member of the Nomination and Remuneration Committee |
| 4. Mr. Nanthiya Darakananda | Director / Chairman of the Risk Management Committee / Chairman of the Executive Committee / Member of the Nomination and Remuneration Committee / Member of the Good Corporate Governance and Sustainability Committee / Chief Executive Officer |
| 5. Mr. Amarin Pataranavig | Director |
| 6. Ms. Jinhatha Panyasorn (D.D.S) | Director |
| 7. Mr. Tanakorn Vidhayasirinun | Director / Member of the Risk Management Committee |

Director(s) was not present at the Meeting (Out sick)

- | | |
|------------------------------|--|
| 1. Mr. Nattaphol Vimolchalao | Independent Director / Member of the Audit Committee |
|------------------------------|--|

The Company has a total of 8 directors and 7 of whom were present at the Meeting, representing 87.5 percent of the Company’s directors.

Executive present at the Meeting

- | | |
|-----------------------------|--|
| 1. Mr. Rachan Arayawongchai | Member of the Risk Management Committee / Executive Director / Chief Finance Officer |
|-----------------------------|--|

The Meeting commenced at 10.00 hrs.

Ms. Sita Potipipith, appointed by the Board of Directors to serve as the Moderator at the Meeting (the "**Moderator**"), welcomed all Shareholders attending the 2026 Annual General Meeting of Shareholders via electronic meeting. The Moderator thereafter informed the Shareholders that the Meeting was held electronically in compliance with the Emergency Decree on Electronic Meetings B.E. 2563 and the Notification of Ministry of Digital Economy and Society Re: Standards for Maintaining Security of Meeting via Electronic Means B.E. 2563. Accordingly, the Company had arranged an electronic meeting service provider having expertise and certified by the relevant agency. Additionally, the Company had arranged a representative from an outside legal consultant firm to inspect the voting procedures and facilitate the Meeting to proceed in a transparent and lawful manner and in accordance with the Articles of Association and the Corporate Governance Principles.

The Moderator informed the shareholders that this meeting is being broadcast via video conference from the Company's headquarters. Shareholders may verify their identity and register for the meeting by following the instructions provided in Enclosure 8, which was sent along with the notice of the meeting.

Subsequently, the Moderator proceeded to introduce the members of the Board of Directors and the Executive Management team:

- | | |
|---------------------------------------|--|
| 1. Asst Prof Dr. Terdsak Rojsurakitti | Independent Director / Chairman of the Board of Directors / Chairman of the Good Corporate Governance and Sustainability Committee / Chairman of the Nomination and Remuneration Committee |
| 2. Mr. Chanat Sorakraikitikul | Independent Director / Chairman of the Audit Committee |
| 3. Dr. Renu Ubol | Independent Director / Member of the Audit Committee / Member of the Good Corporate Governance and Sustainability Committee / Member of the Nomination and Remuneration Committee |
| 4. Mr. Nattaphol Vimolchalao | Independent Director / Member of the Audit Committee
(Absent due to sick leave) |
| 5. Mr. Nanthiya Darakananda | Director / Chairman of the Risk Management Committee / Chairman of the Executive Committee / Member of the |

	Nomination and Remuneration Committee / Member of the Good Corporate Governance and Sustainability Committee / Chief Executive Officer
6. Mr. Amarin Pataranavig	Director
7. Ms. Jinhatha Panyasorn (D.D.S)	Director
8. Mr. Tanakorn Vidhayasirinun	Director / Member of the Risk Management Committee

Executive present at the Meeting

1. Mr. Rachan Arayawongchai	Member of the Risk Management Committee / Executive Director / Chief Finance Officer
-----------------------------	--

The Moderator then informed the Meeting that the Company had invited the auditors from ANS Audit Company Limited: namely Ms. Atchara Suknaibaiboon and Ms. Anusara Chatsoonthorn, to attend the Meeting via electronic media to address any inquiries from shareholders regarding the Company's financial statements.

Regarding the inspection of the Meeting and votes for each agenda item, Ms. Prathomporn Fungkhumdee, an independent legal consultant from PRO LEGAL & I.P. CO., LTD., who had no vested interest in the Company, was invited to attend the Meeting via electronic device, in order to ensure the transparency of voting procedures, and facilitating the Meeting to proceed in a transparent and lawful manner and in accordance with the Company's Articles of Association and Corporate Governance Principles.

In this Meeting, the Company had determined a list of Shareholders eligible for participating the 2026 Annual General Meeting of Shareholders (Record Date) in accordance with the Securities and Exchange Act B.E. 2535 (Article 89/26) as 17 March 2026. Further details were available on website of the Stock Exchange of Thailand (SET) which showed important information of the Company, including a list of the first 10 shareholders and various news.

The Company had offered the Shareholders an opportunity to submit an additional agenda for the Meeting in accordance with the criteria stipulated by the Company in advance between 3 November 2025, and 31 January 2026. These had been disseminated via the Stock Exchange of Thailand's electronic channels. Nonetheless, no shareholder proposed an additional agenda item for the Meeting.

The quorum of Shareholders was as follows;

1. 1 share equivalent to 1 vote
2. The total number of attendees, attending personally or via proxy, of not less than 25 people
3. The total number of shares of not less than one-third (1/3) of the total paid-up shares or not less than 133,333,333.33 shares

The Moderator informed the Meeting that in the 2026 Annual Meeting of Shareholders, 11 Shareholders attended the Meeting via electronic devices, the total number of shares was 48,410,630 shares, and 19 proxies attended the Meeting and held 244,329,337 shares. In total, there were 27 Shareholders and proxies attending the Meeting with a total number of 239,279,047 shares. This constituted 71.9224% of the total paid-up shares as of 17 March 2026, the date determining the Shareholders' right to attend the 2026 Annual General Meeting of Shareholders (Record Date), which was set at 400,000,000 shares. The quorum required, as stipulated in the Company's Articles of Association, was duly met.

The Moderator then invited Asst. Prof. Dr. Terdsak Rojsurakitti, Chairman of the Board of Directors, who served as the Chairman of the Meeting (the “**Chairman**”), to open the 2026 Annual General Meeting of Shareholders.

The Chairman opened the meeting and thanked the Shareholders for their valuable time attending the 2026 Annual General Meeting of Shareholders. To ensure that the Meeting would proceed effortlessly, the Chairman assigned Ms. Wanwisa Soisawat, the Company's Secretary, to record the Meeting, and Ms. Sita Potipipith, the Moderator, to describe the steps and procedures for conducting the Meeting.

The meeting moderator informed the shareholders that this meeting is being recorded in the form of a video presentation. The Company will collect, use, and disclose personal data, including still images, audio, and video footage of all participants. The shareholders' meeting system is provided by Inventech Systems (Thailand) Co., Ltd. through the Inventech Connect platform, which has been officially registered as a digital platform service under the Royal Decree on Digital Platform Services Requiring Notification B.E. 2565 (2022) with the Electronic Transactions Development Agency (ETDA). The recording and data collection are for the purposes of meeting documentation, report preparation, meeting management, and other related processes. The moderator also explained the meeting procedures and guidelines as follows:

- In voting, each Shareholder's vote would be proportional to the number of shares held and granted to them, implying 1 share equivalent to 1 vote.
- Shareholders and proxies using the proxy form A. and B. have only one way to vote, i.e., approve, disapprove, or abstain, without the possibility of separating the votes on each agenda. Nevertheless, the votes can be split into separate votes for a custodian shareholder who uses the proxy form C. If the

grantor has already indicated his/her wish to vote, the votes will be recorded as stated in the proxy form from the time of commencing the Meeting.

- For Agenda 4, to consider and approve the appointment of directors in replacement of those due by rotation for 2026, the Company proposed to select the director individually according to Article 16 of the Company's Articles of Association.
- The vote-counting base for each agenda may not be equal due to the possibility of additional Shareholders and proxies attending during the Meeting.

Procedures for Voting, Vote Counting, Questioning, or Commenting were as follows:

1. The Meeting shall consider the matter in the order of Agendas specified in the invitation letter to the Meeting. In this regard, information will be presented on each agenda, allowing Shareholders to ask questions before voting, and the results will be reported at the conclusion of the vote count.
2. In voting, the Shareholders may choose the agenda item they wish to vote for. Then press the "Vote" button. The system will display all 3 voting channels: approve, disapprove, and abstain.

The system displays all lists of Shareholders who have granted proxies to Shareholders or those who have been granted multiple proxies. Ballots are separated into individual user accounts for voting.

To revoke a vote, press the "Revoke the Vote" button. For Shareholder who has not cast a ballot within the allotted time, the Company shall deem that such Shareholder has approved such agenda. Voting may be modified until the Company notifies a notice of closure and the Company allows 1 minute for voting. Once voting has concluded for each agenda item, the Meeting controller will process the vote, and the Secretary of the Meeting will announce the result, which will be given to the Meeting promptly before commencing the next agenda item.

After the vote has concluded and the Secretary has announced the vote closed, the attendees are no longer eligible to vote on such agenda.

3. Shareholders for whom multiple Shareholders have granted proxies, please press "User Account" and "Change Account" to access the accounts of other Shareholders. No ballots will be removed from the voting pool.
4. By counting the votes, the Company will deduct disapproval and abstention ballots from the total number of votes when tallying the votes. The remaining ballots will be deemed as approval votes.
5. If a Shareholder decides to leave the Meeting prior to the ending of any vote, the Shareholder's vote will not be counted as quorum in such agenda and the vote will simultaneously not be counted in the remaining agenda. However, leaving the Meeting under any circumstances in any agenda will not prejudice the Shareholders' or proxies' right to return to a subsequent Meeting and vote in the next agenda in the system.
6. Questions or Comments in the Meeting

Before casting a vote in each agenda, the Company will provide attendees with at least 1 minute to ask questions or comment on matters relating to each agenda item, as deemed appropriate. For questions or comments on matters not directly relating to such agenda item, the Company asks for cooperation to provide questions or comments after the conclusion of agenda item 8, which is the last agenda. The Shareholders may select an agenda desired to question or comment, then select the "Question" button, and questions could be asked via two channels as follows:

- Question Via text message: By typing the question then press “Submit”. The Company will answer questions in the Meeting room in the agenda concerning such matters. Nevertheless, if many questions are submitted, the Company reserves the right to select questions as appropriate, or
- Question via VDO Conference: By pressing the "Question via VDO Conference" and press "OK" buttons to confirm your queue. Once authorized by the staff, turn on the camera and microphone. Before each query, attendees must notify the Company of their name, surname, and status as Shareholders or proxies so that the Company can keep a complete record of the Meeting's Minutes. If the VDO conference channel is interrupted during the Meeting, the shareholders are requested to ask the questions via text message instead.

The Company reserves the right to turn off the image and voice of Shareholders who submit impolite questions or comments, make fraudulent or derogatory statements to other Shareholders, or violate any law, including violating the rights of others, disrupting the Meeting, or harassing other attendees.


7. In case many Shareholders desire to ask questions via the video conference system, the Shareholders are asked to submit their questions via text message for the staff to answer in order to maintain the appropriate duration of the Meeting. Due to the time limitation, if any questions cannot be answered during the Meeting, the Company will answer them at the end of the Meeting or will consider compiling the questions and answers of the directors for publication in the Meeting's Minutes and the Company's website.
8. If Shareholders experience any difficulties accessing the Meeting or voting system, please study and follow the instructions included with the Meeting’s invitation letter or select the "Help" menu in the system. Inventech Call Center staff can be reached via phone numbers and Line Official.
9. If the system fails during the Meeting, Shareholders will further receive an email instructing them to return to the Meeting through the backup system.

Before commencing to consider the agendas, the Moderator asked the Shareholders if they had any questions about the criteria and voting procedures. However, no shareholder posed questions. The Moderator then invited the Chairman of the Board of Directors who served as the Chairman of the Meeting to consider the agenda items included in the invitation letter to the Meeting.

Agenda 1 To acknowledge the Company Group's 2568 (2025) Annual Performance

The Chairman assigned Mr. Rachan Arayawongchai, the Chief Financial Officer (the “CFO”) to report this matter.

Then, Mr. Rachan Arayawongchai, the CFO, briefed the Meeting on the details of this agenda item, as follows





Revenue Decline factors

เลือกตั้งนายก อบจ., สส.ทั่วประเทศ

- หน่วยงานท้องถิ่นหลายจังหวัดเลื่อนหรือชะลอกิจกรรมตรวจคัดกรองมะเร็งปากมดลูก
- ความไม่แน่นอนด้านนโยบายพื้นที่หลังการเลือกตั้ง

การตรวจคัดกรองมะเร็งปากมดลูกลดลง

- กฎเกณฑ์และข้อจำกัดของภาครัฐ
- จำนวนผู้หญิงที่เข้ารับการตรวจลดลง


Regarding the Company's revenue structure, the BSM business group saw an increase of approximately 26.39 million Baht (17%), while the CMT business group grew by 19.64 million Baht (33%). This reflects the rising demand for Immunotherapy and CAR-T Cell technologies. Additionally, the Consumer Product segment also showed growth. However, revenues for the MBS and SRC groups declined, primarily due to the following two factors:

Point 1: The Blood Bank business group has undergone a contract restructuring, involving changes to both contract formats and payment terms. Previously, the Company utilized Sales and Purchase Agreements for reagents with no volume commitment, where revenue was recognized upon delivery. This has transitioned to Medical Equipment Lease Agreements with monthly payment terms based on completed test reports. Consequently, this shift has impacted the timing of revenue recognition. In this regard, the auditors have adjusted the Company's revenue recognition process to comply with Thai Financial Reporting Standard 15, resulting in a deferred recognition of revenue in the financial statements.

Point 2: The nationwide Provincial Administrative Organization (PAO) elections held in late 2024 through Q1 2025, followed by the General Election after the dissolution of Parliament last December, have caused delays in project approvals and cervical cancer screening activities. This is particularly evident in provincial areas where the appointment of new executive teams and the official budget allocation process

are still pending. Furthermore, stricter government regulations now require individuals to verify their identity in person for screenings. This has impacted service volume and led to a decline in revenue. However, the Company has launched proactive health caravans to provide on-site services, reducing access barriers for the public. The Company anticipates that this initiative will support the long-term recovery of this business group's revenue.

– Figure showing Lists of the total 19 locations per region –



Mobile Blood Collection

ภาคกลาง+ตะวันออก	ภาคอีสาน	ภาคใต้
1.สว.ราชวิถี	1.สว.ขอนแก่น	1.สว.ยะลา
2.ศูนย์การแพทย์สมเด็จพระเทพรัตน์ (มศว.)	2.สว.ร้อยเอ็ด	2.สว.วชิระภูเก็ต
3.สว.พระจอมเกล้าเพชรบุรี	3. สว.บุรีรัมย์	3.สว.สงขลา
4.สว.รามารินทร์ดี	4.สว.วังสะพุง	4.สว.ตรัง
5.สว.ธรรมศาสตร์	5.สว.กาฬสินธุ์	5.สว.สุราษฎร์ธานี
6.สว.ชลบุรี	6.สว.นครราชสีมา	
7.สว.วชิรพยาบาล	7.สว.มหาสารคามนครราชสีมา	


In 2025, the Company expanded its partnership with hospitals by adding 9 additional mobile blood collection units, namely: Chonburi Hospital, Vajira Hospital, Wang Saphung Hospital, Kalasin Hospital, Nakhon Ratchasima Hospital, Maharat Nakhon Ratchasima Hospital, Songkhla Hospital, Trang Hospital, and Surat Thani Hospital. These units are distributed across various regions, bringing the Company's total number of collaborative mobile blood collection units to 19 locations to date.

ส่งมอบเครื่อง CliniMACS Prodigy

เพื่อใช้ในการรักษาผู้ป่วยธาลัสซีเมีย และทำ Chimeric Antigen Receptor T-Cell Therapy (CAR T-Cell)



Regarding the delivery of the CliniMACS Prodigy in 2025, one unit was supplied to a public sector agency for the treatment of Thalassemia and Chimeric Antigen Receptor T-Cell Therapy (CAR T-Cell) for blood cancer. Furthermore, the Company has achieved consistent sales of the reagents used in conjunction with the device and plans to deliver additional units within this year.



Regarding the health screening projects under the National Health Security Office (NHSO) reimbursement scheme and other health services, the Company has proceeded to sign Memorandums of Understanding (MOU) with 13 additional Provincial Administrative Organizations (PAOs), as highlighted in red on the diagram. Furthermore, several other provinces are currently in the negotiation phase. As a result, the total number of provinces collaborating with the Company, including both those with signed MOUs and those without MOUs but currently sending test kits to the Winmed Health Center, has increased to 23 provinces.

คาราวานตรวจสุขภาพ



OUR Activities

โครงการคาราวานตรวจสุขภาพเคลื่อนที่ร่วมกับท้องถิ่น
ชัยภูมิ, โคราซ, อำนาจเจริญ, บุคดาหาร, กาฬสินธุ์,
ท่าแพงเพชร, นครสวรรค์, สมุทรสาคร, ปทุมธานี



นครสวรรค์



สมุทรสาคร




ปทุมธานี

Regarding the Company's mobile health caravan activities conducted in collaboration with local authorities over the past year held in provinces, such as Chaiyaphum, Korat, Amnat Charoen, Mukdahan, Kalasin, Kamphaeng Phet, Nakhon Sawan, Samut Sakhon, and Pathum Thani, the initiative received significant public interest, with a steady and continuous stream of service users across multiple areas.

KEY PROJECTS

in 2026



Life Sciences



Blood Solutions



Cancer Care



Consumer

In 2026, the Company will move forward with key projects across all business segments as planned to strengthen the Company's foundation and expand opportunities for sustainable growth. Within the Life Sciences group, the Company will advance cell and molecular technologies to provide cutting-edge medical options for medical schools and research institutions. In Blood Solutions, the Company's focus is on enhancing the efficiency of blood donation and management systems to meet the rising nationwide demand for blood and platelets. For Cancer Care, the Company aims to expand access to screenings for cervical and other cancers, promoting a proactive healthcare mindset. Lastly, in Consumer Products, the Company is developing home healthcare products, including mosquito and blood-sucking insect traps, which cater to both general consumers and the growing pet-owner market. These initiatives are the heart of the Company 2026 strategy to improve the quality of life for Thais and ensure the Company's robust, long-term growth.



**Cell
Molecular
Technology**

Existing Customer

- คณะแพทยศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย : มะเร็งเต้านม, CAR T-cell
- คณะแพทยศาสตร์ ศิริราชพยาบาล : CAR T-cell
- คณะแพทยศาสตร์ โรงพยาบาลรามาธิบดี : ธาลัสซีเมีย, CAR T-cell

The advertisement features a light blue background on the left with the title 'Cell Molecular Technology' in large, bold, dark blue letters. A small inset photo shows two medical professionals in white coats. Below the title is a list of existing customers. On the right, a photograph shows a smiling woman with a shaved head being embraced by another woman and a young child. A small WinnergyMEDICAL logo is in the top right corner of this photo.

A core pillar of the Company's business is increasing access to immunotherapy, which plays a critical role in modern cancer treatment. The Company has earned the trust of several leading medical institutions in Thailand that utilize the Company's technologies. This includes the Faculty of Medicine, Chulalongkorn University, for breast cancer and CAR T-cell treatments; the Faculty of Medicine Siriraj Hospital, for treating blood cancers with CAR T-cell therapy; and the Faculty of Medicine Ramathibodi Hospital, for treating Thalassemia and blood cancers. These collaborations reflect the Company's strong potential in supporting high-level medical technology, empowering physicians to provide advanced care to an increasing number of patients.

KEY PROJECT



การพัฒนาผลิตภัณฑ์และนวัตกรรมใหม่
ของศูนย์บริการโลหิตแห่งชาติ สภากาชาดไทย

แหล่งที่มาของข้อมูล : รายงานประจำปี 2567 ของศูนย์บริการโลหิตแห่งชาติ สภากาชาดไทย เผยแพร่วันที่ 20 ตุลาคม 2568 (หน้าที่ 29)

Another key initiative this year is the Pathogen Inactivation project (or “PI”), which has been officially included in the annual report of the National Blood Centre, Thai Red Cross Society. This inclusion highlights a significant policy shift as Thailand increasingly prioritizes the elevation of safety standards for blood products, particularly in enhancing the safety of platelets. The PI process is designed to ensure 100% platelet safety. Recognized as one of the National Blood Centre’s new innovations, this project reflects both the Company’s technological progress and positive strategic direction.

PI Partnership Project



สว.จุฬาลงกรณ์ สภากาชาดไทย



สว.พระมงกุฎเกล้า



สว.ธรรมศาสตร์



สว.ราชวิถี



สว.ภูมิพล



สว.ศิริราช ปิยมหาราชการุณย์



คณะแพทย์ ม.นเรศวร



สว.พญาไท 2

To date, the Company has surveyed more than 70 public and private hospitals nationwide for the PI project to assess the potential and readiness for implementing PI technology within their blood bank systems. As illustrated in the diagram above, this effort included on-site seminars and technical presentations at 8 leading hospitals, namely: King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Phramongkutklao Hospital, Thammasat University Hospital, Rajavithi Hospital, Bhumibol Adulyadej Hospital, Siriraj Piyamaharajkarun Hospital, the Faculty of Medicine at Naresuan University, and the National Blood Center, Thai Red Cross Society. The engagement from these institutions reflects a high level of interest and positive reception toward the said technology.



WINMED Mobile Blood Collection Bus

WINMED ให้บริการด้วยรถบัสเคลื่อนที่ สำหรับการรับบริจาคเกล็ดเลือด

จุดเด่นของโครงการ

- ออกแบบตามมาตรฐานความปลอดภัยของศูนย์บริการโลหิต
- รองรับบริการบริจาคเกล็ดเลือดด้วยเทคโนโลยี Apheresis System
- ภายในรถมีจุดลงทะเบียน เก็บตัวอย่าง และเตียงบริจาคครบวงจร
- ควบคุมอุณหภูมิและความสะอาด เพื่อความปลอดภัยของผู้บริจาค

พื้นที่ให้บริการ

- กรุงเทพฯ และปริมณฑล
- รองรับได้ครั้งละ 5 เครื่อง
- พื้นที่ที่มีข้อจำกัด อาทิ สถานที่แคบ ร้อน ห่างไกล

รองรับการบริจาคได้

2,000

Sets : คับ : ปี

The Mobile Blood Donation Bus project is designed in strict accordance with the safety standards of the National Blood Centre, featuring an international-standard Apheresis System. The bus serves as a comprehensive, one-stop unit, comprising a registration area, a blood sampling station, and five donation beds. It is fully equipped with advanced temperature and cleanliness control systems to ensure maximum donor safety. The mobile unit will operate within Bangkok and its vicinity, targeting areas with space and weather constraints. The utilizing of a mobile bus enhances convenience and broaden donor access, with an estimated capacity of 2,000 sets per bus annually. The Company expects to launch this service by the end of the second quarter of 2026.

CERVICARE AI



Marketing Strategies

- KOL Campaign
- Conference Booths
- Digital & PR
- Workshop

กลุ่มเป้าหมาย

- วิจัยร่วมกับโรงเรียนแพทย์ 17 สถาบันชั้นนำ
- Existing Customers : คลินิกนครสวรรค์, คลินิกออมทอง
- คาราวานร่วมกับ Winthai (เช่าเครื่อง) : ออมง.มุกดาหาร, ออมง.ท่าแพงเพชร

For Cervicare AI, the Company prioritizes proactive mobile caravans, by which field units and sales teams work in close coordination to simultaneously expand service accessibility and capture new business opportunities on the ground.

การสนับสนุนการวิจัย จัดทำโดยสมาคมมะเร็งนรีเวชไทย ร่วมกับทีมวิจัย 17 สถาบัน



In addition, the Company has conducted collaborative research with the Thai Gynecologic Cancer Society (TGCS), involving a total of 17 leading medical institutions. This includes the Faculty of Medicine Siriraj Hospital, Mahidol University, and others, as listed among the 17 institutions shown in the image above.

NURSE SERVICE



Furthermore, the Company conducted a Nurse Service initiative in Kamphaeng Phet province, where the mobile caravan operated continuously for over 11 days. The program saw an average of more than 300 attendees per day for educational lectures, with 30–40 patients per day receiving colposcopy screenings. This activity highlights the strong demand for screening services in provincial areas and demonstrates the effectiveness of our caravan model in creating both social impact and consistent utilization of our medical equipment.



คนในครอบครัว
เคยเป็นมะเร็งเต้านม?
หากใช่...คุณเสี่ยง
มากกว่าคนทั่วไปหลายเท่า

ตรวจเลยวันนี้ ก่อนจะสายเกินไป...
เพื่อตัวคุณเองและคนที่คุณรัก

THERMOGRAM.AI

โปรแกรมตรวจ
คัดกรองมะเร็งเต้านม
Thermogram.AI

จองคิวตรวจผ่าน LINE OA
@winmedhealth หรือ



สะดวก เป็นส่วนตัว
ไม่มีรังสีอันตราย

Another key project is THERMO GRAM AI, a breast cancer screening technology that utilizes AI-powered image analysis, with results verified by expert radiologists before being delivered to clients. This project addresses the need for early-stage screening, particularly for high-risk individuals with a family history of breast cancer. It offers a convenient, accessible, and affordable alternative. Currently, the service is available at the Winmed Health Center, and we are in the process of expanding service points to meet growing demand. Clients can choose to walk in to our clinic or book an appointment via our Line Official Account (Line OA) as shown above.

Furthermore, the Company plans to scale this service to the general public through health caravan projects in collaboration with Provincial Administrative Organizations (PAOs) nationwide. This initiative aims to provide Thai women with more convenient access to breast cancer screenings. Ultimately, the Company hope to play a vital role in protecting Thai women from this disease, which aligns perfectly with the Company's Meaningful Purpose: "Zero Deaths from Cancer".

CMK BLACKHOLE



Stabilize Traditional Channels

80% Revenue Optimize existing channels



Expand Pet Market

20% Revenue Pet Expo + Vet Network



Online



HomePro Expo



Modern Trade



Service

For our Consumer Product group, the Company focuses on two core strategies. First, the Company is securing our primary revenue base, with over 80% of sales coming from Modern Trade channels. While previously limited to HomePro, we have now expanded the product line into the Thai Watsadu group. Second strategy focuses on market expansion, with the remaining 20% of revenue driven by entering into the Pet Market. This achievement was from the Company's participation in Pet Expo events and by building a nationwide network of veterinary clinics to reach the steadily growing pet-owner segment. Regarding communication and sales, the Company prioritizes online campaigns to raise awareness about home and pet safety, which has effectively boosted sales and expanded the customer base. Furthermore, the Company dedicated after-sales service continues to build long-term trust across all customer segments.

– Figure showing WINMED's award on Corporate Governance Report of Thai Listed Companies 2025–



Furthermore, in 2025, the Company is extremely proud to have received two corporate governance and regulatory assessment awards from the Thai capital market for the third consecutive year:

- An Excellent CG Scoring (5 stars) from the Thai Institute of Directors (IOD).
- A perfect score of 5 out of 100 for the quality of the Annual General Meeting of Shareholders.

These awards reflect the Company's commitment to conducting business with transparency and prioritizing the well-being of all stakeholders. The Company will continue to strive for and enhance its corporate governance to build sustainable trust with investors and society.

The Moderator provided further updates to the Meeting regarding the ongoing efforts to combat corruption and collusion within the Company. Currently, the Company was in the process of studying the overall certification process to consider participating in signing the integrity pledge with the Thai Private Sector Collective Action Coalition Against Corruption (CAC) with more progress than the previous year. However, the Company currently had an effective internal anti-corruption framework in place and a sufficient internal control system to prevent corrupt practices within the organization.

The Moderator subsequently offered shareholders and proxies the opportunity to inquire about the Company Group's 2568 (2025) Annual Performance Report through the specified channel(s).

The Moderator informed the Meeting that one participant, Ms. Chantarawan Charoontham, who was present in person, had questions regarding this agenda item. She posed 4 questions, and to ensure clear responses, the Moderator announced the questions to the committee member one by one as follows:

Question 1 (From a shareholder attending the meeting in person, Ms. Chantharawan Charoontham)

What caused the revenue from Product Group SRC to decrease in 2025?

Answer by Mr. Nanthiya Darakananda, the Chief Executive Officer

Regarding this question, Mr. Rachan Arayawongchai, Chief Financial Officer, has already explained part of it as previously clarified. Therefore, I would like to provide some additional answers as follows:

Firstly, the recent Provincial Administrative Organization (PAO) elections have disrupted the Company's fieldwork.

Secondly, the Company is in a phase of strengthening its caravan teams. It's noticeable that the Company hasn't stopped investing in personnel because it needs to expand its caravan operations, including field work related to blood donation and other activities. This is part of the Company's efforts to keep up with the growing demand, which is why there were delays in several areas last year.

The next point concerns the competitive landscape following the COVID-19 pandemic. We have seen rapid advancements in Molecular Technology for various diseases, as evidenced by the influx of COVID-19 test kits from numerous countries. Similarly, the HPV testing market has become increasingly commoditized, with many new manufacturers entering the field, leading to market volatility. However, while the testing market may fluctuate, the demand for cervical cancer care remains steady. The Company's unwavering focus remains our mission: Zero Deaths from Cancer, particularly cervical cancer. The Company do not view our business as merely providing tests; we look at the entire journey to close the loop on the problem. The Company ensures that those who test positive can seamlessly proceed to the next stage of treatment. The Company recognized a critical pain point for patients: the immense anxiety and long wait times between a positive HPV result and receiving a colposcopy. This is due to a significant shortage of colposcopists in Thailand, creating a major bottleneck. To address this, as mentioned by Mr. Rachan Arayawongchai, we have introduced AI Colpo technology. This breakthrough has garnered interest from 17 leading institutions currently collaborating with us to bring this process to life. The Company has further integrated AI Colpo into Mobile Units to provide on-site diagnostics and care. In summary, while basic technology is being commoditized, the Company is moving beyond mere HPV testing, and building a continuous care model that drives growth and fulfills the ultimate goal: reducing the mortality rate of Thai women from cervical cancer to zero.

Question 2 (From a shareholder attending the meeting in person, Ms. Chantharawan Charoontham)

Is Thin Prep currently being replaced by HPV DNA testing, and if so, how?

Answer by Mr. Nanthiya Darakananda, the Chief Executive Officer

Thin Prep is a long-developed asset currently owned by Hologic, Inc. Thin Prep is a cytological testing method, while the HPV DNA Test is a molecular method. As previously explained, the molecular method is quite volatile and faces competition from many companies offering similar cytological testing kits. Both of these businesses demonstrate a competitive landscape with high-quality products. However, considering only the sales aspect, the problem is that there are still many people who could be eligible for the National Health Security Office (NHSO) benefits but lack access to screening and treatment if diagnosed with cancer. The NHSO's policies highlight a gap that needs addressing. The solution lies in the Company's identification of the critical pain points of its customers or patients. Customers are not simply looking for a test to find out if they are HPV positive or negative; they want to know if they have cervical cancer, and if so, how they can be tested and treated as quickly as possible. Therefore, the Company's challenge, while initially viewed as a volatile market, can be seen from a broader perspective of cervical cancer awareness as a vast blue ocean. Currently, the Company is well-prepared to address this issue because it offers a comprehensive range of products, including those for cytology sample collection, molecular gastronomy, mRNA systems, DNA systems, and PCR. Thus, the Company has a complete solution for this problem.

Question 3 (From a shareholder attending the meeting in person, Ms. Chantharawan Charoontham)

Regarding the signing of MOUs in 2025, considering that the Company has signed MOUs with many Provincial Administrative Organizations (PAOs) in various provinces, how will the Company manage or resolve issues in working with Provincial Administrative Organizations (PAOs), Sub-district Health Promotion Hospitals (HPHs), and Village Health Volunteers (VHVs) to ensure continuous testing according to the planned targets, including addressing limitations with the National Health Security Office (NHSO)?

Answer by Mr. Nanthiya Darakananda, the Chief Executive Officer

Regarding this question, Mr. Rachan Arayawongchai, Chief Financial Officer, has already explained part of the Mobile and Caravan initiatives. The Company has invested heavily in technology and relationships to foster collaboration for the use of caravans in various provinces. This has been ongoing and continuously expanding, earning the trust of the public

receiving services and the confidence of medical services and local government agencies, including Provincial Administrative Organizations and community hospitals. It can be observed that the Company has continuously signed MOUs for business expansion every year, and those that have expired have been extended for additional years. These actions reflect to shareholders or investors that the Company's approach has been correct, and that the Company is now expanding into other testing areas as proposed by Mr. Rachan Arayawongchai, such as thermograms. The Company has begun including thermogram packages with the caravan groups, and now has a large number of mobile blood donation units. All of these initiatives can be implemented collaboratively.

Question 4 (From a shareholder attending the meeting in person, Ms. Chantharawan Charoontham)

Regarding the latest annual report, which includes distributor agreements, the Company currently does not have a Grifols contract. The question is whether this contract was not renewed. And for other key partners such as Haemonetics, Hologic, Helmer, and Miltenyi Biotec, whose contracts expire in 2026, does the Company anticipate renewing them, and how does it manage this risk? Is there a possibility that these contracts will not be renewed?

Answer by Mr. Nanthiya Darakananda, the Chief Executive Officer

In the distributor business, there may be cases where contracts are not renewed, or the Company itself may not wish to renew them. This is because technology is unsustainable and can be disrupted by both competitors and the Company itself, as has happened many times throughout the 30 years the Company has been in business. While the Company is no longer a partner with Grifols, it currently collaborates with existing Grifols distributors and offers alternative products to Grifols. If investors are medical professionals and attend trade shows or academic conferences that are frequently held in Thailand, they will see that the Company has a presence and will notice new products that have been introduced to replace or supplement existing products.

Regarding the question of whether other businesses are continuing, the Company continues to operate with all of them. However, the Company chooses to do business with each one from a different perspective. Currently, if you look at the product portfolio, the Company has a large number of products, some already on the market, some imported to replace existing products, some to disrupt competitors, some as supplementary businesses, and some as core businesses. Similarly, the Company has earned the trust of well-known Chinese medical equipment manufacturers such as Haier and Midea, who rely on the Company as their distributor, and the Company has performed quite well for those Companies. As for Miltenyi, the Company has been continuously expanding, and this year has seen particularly significant growth. Looking at global trends, immunotherapy products

are quite popular, whether in Japan, the USA, Europe, India, or many other countries that have launched these products. This should be contingent on Thailand's regulations aligning with the countries where the products are sold. Thailand, being a hub for treatment in the region, is seen as having potential for immunotherapy products. If regulations align with those of China, Europe, or the United States, this business is expected to experience exponential growth. Therefore, given the growth of healthcare services, the Company is not stopping its efforts on products and substitutes. This is evident from the fact that this year, the Company's team has been actively searching for new products, meeting with new suppliers, and undergoing extensive training.

As there was no further additional question or comment being raised from the Shareholders, the Moderator thus informed the Meeting that this Agenda was for acknowledgement and voting was not required.

Resolution The Meeting acknowledged the Company Group's 2568 (2025) Annual Performance Report

Agenda 2 To approve the Company's Financial Statements for the year ended December 31, 2025

The Chairman appointed Mr. Rachan Arayawongchai, the CFO, to report this matter to the Meeting.

– Figure showing a summary of the auditor's report on the Company's Financial Statements for the year ended December 31, 2025 –

วาระที่ 2 พิจารณานุมัติงบการเงินประจำปีสิ้นสุดวันที่ 31 ธันวาคม 2568



ประเภทรายงานของผู้สอบบัญชีในงบการเงิน : ความเห็นอย่างไม่มีเงื่อนไขและไม่มีข้อสังเกต / เรื่องอื่น

ความเห็น

ข้าพเจ้าเห็นว่า งบการเงินรวมและงบการเงินเฉพาะกิจการข้างต้นนี้แสดงฐานะการเงินรวมและฐานะการเงินเฉพาะกิจการของบริษัท วินเนอร์มีเดียคอล จำกัด (มหาชน) และบริษัทย่อย และของเฉพาะบริษัท วินเนอร์มีเดียคอล จำกัด (มหาชน) ตามลำดับ ณ วันที่ 31 ธันวาคม 2568 ผลการดำเนินงานรวมและผลการดำเนินงานเฉพาะกิจการ และกระแสเงินสดรวมและกระแสเงินสดเฉพาะกิจการสำหรับปีสิ้นสุดวันเดียวกันโดยถูกต้องตามที่ควรในสาระสำคัญตามมาตรฐานการรายงานทางการเงิน

เรื่องสำคัญในการตรวจสอบ

เรื่องสำคัญในการตรวจสอบคือเรื่องต่าง ๆ ที่มีนัยสำคัญที่สุดตามดุลยพินิจของผู้ประกอบวิชาชีพของข้าพเจ้าในการตรวจสอบงบการเงินรวมและงบการเงินเฉพาะกิจการสำหรับปีปัจจุบัน ข้าพเจ้าได้นำเรื่องเหล่านี้มาพิจารณาในบริบทของการตรวจสอบงบการเงินรวมและงบการเงินเฉพาะกิจการโดยรวมและในการแสดงความเห็นของข้าพเจ้า ทั้งนี้ ข้าพเจ้าไม่ได้แสดงความเห็นแยกต่างหากสำหรับเรื่องเหล่านี้

(For details please see below)

Mr. Rachan Arayawongchai, Chief Financial Officer, explained the details of this agenda item to the Meeting as follows:

The auditor's report on the financial statements is an unqualified opinion without any other concerns or observations. The auditor's opinion is that the consolidated and separate financial statements presented above show the consolidated and separate financial positions of Winnergy Medical Public Company Limited and its subsidiaries, and of Winnergy Medical Public Company Limited alone, as at December 31, 2025. The consolidated and separate financial statements and cash flows for the year ended on the same date are presented fairly in all material respects in accordance with financial reporting standards. The matters of the audit are those that are of the greatest significance in the professional judgment of the auditor in auditing the consolidated and separate financial statements for the current year. The auditors have taken these matters into consideration in the context of the audit of the consolidated and separate financial statements as a whole and in expressing their auditor's opinion. However, the auditors have not expressed separate opinions on these matters.

– Figure showing the Statement of Comprehensive Income in 2025 (B.E.2568) and 2024 (B.E. 256) –

Statement of Comprehensive Income



Statement of Comprehensive Income	2568		2567		Increase (Decrease)	
	(Million Baht)	Proportion	(Million Baht)	Proportion	(Million Baht)	% Change
รายได้จากการขายและบริการ	595.47	92.03%	602.09	92.01%	(6.62)	(1.10%)
รายได้ค่าเช่า	51.56	7.97%	52.26	7.99%	(0.70)	(1.34%)
รวมรายได้	647.04	100.00%	654.36	100.00%	(7.32)	(1.12%)
ต้นทุนขายและบริการ	(338.64)	(56.87%)	(355.56)	(59.05%)	16.92	(4.76%)
ต้นทุนค่าเช่า	(32.08)	(62.22%)	(32.14)	(61.49%)	0.06	(0.17%)
รวมต้นทุนขาย	(370.72)	(57.30%)	(387.69)	(59.25%)	16.98	(4.38%)
กำไรขั้นต้น	276.32	42.70%	266.66	40.75%	9.65	3.62%
รายได้อื่น	26.58	4.11%	21.67	3.31%	4.91	22.66%
ต้นทุนในการจัดจำหน่าย	(121.66)	(18.80%)	(113.33)	(17.32%)	(8.33)	7.35%
ค่าใช้จ่ายในการบริหาร	(146.26)	(22.60%)	(128.86)	(19.69%)	(17.40)	13.50%
กำไร (ขาดทุน) ก่อนต้นทุนทางการเงินและภาษี	34.98	5.41%	46.14	7.05%	(11.16)	(24.19%)
ต้นทุนทางการเงิน	(15.91)	(2.46%)	(12.17)	(1.86%)	(3.74)	30.75%
กำไรก่อนค่าใช้จ่ายภาษีเงินได้	19.07	2.95%	33.97	5.19%	(14.90)	(43.86%)
ค่าใช้จ่ายภาษีเงินได้	(3.90)	(0.60%)	(4.71)	(0.72%)	0.81	(17.28%)
กำไรสำหรับปี	15.17	2.34%	29.26	4.47%	(14.09)	(48.15%)

In 2024, the Company gained a comprehensive income from the operations totaling 647.04 million Baht, decreasing from 2024 by 7.32 million Baht or equivalent to 1.12%. The net profit for the year was 15.17 million Baht, a decrease of 14.09 million Baht from the previous year. The main reason for this decrease is the information detailed in Agenda Item 1. It can be seen that the main expenses that increased include:

- Distribution costs increased by 8.33 million Baht, or 7.35%, primarily due to marketing activities to promote the Company's products, build relationships with medical personnel and related organizations, and depreciation of buildings and building improvements resulting from the acquisition of a building for warehouse use as resolved at the 2024 Annual General Meeting of Shareholders.
- Administrative expenses increased by 17.40 million Baht, or 13.50%, primarily due to increased personnel costs resulting from the Company's business expansion, including the Mobile Blood Collection service, which now has more than 30 service units in various areas. This also includes collaborations with 19 leading hospitals, as well as travel and operational expenses related to expanding partnerships, sourcing new products from overseas, and costs associated with developing new business ventures for the Company, all in line with long-term strategic business expansion and investment plans.

In addition, the auditors have made an adjustment to the accounting entry for expected credit losses arising from contractual receivables. This is a one-time item and has resulted in a decrease in the Company's profit for this year.

– Figure showing the consolidated balance sheet as of 31 December 2025 (B.E.2568) and 31 December 2024 (B.E.2567), and the differences –

Consolidated Balance Sheet

งบแสดงฐานะทางการเงิน	ณ 31 ธ.ค. 2568		ณ 31 ธ.ค. 2567		ผลต่าง	
	งบตรวจสอบ		งบตรวจสอบ		ล้านบาท	% เทียบ 31 ธ.ค.2567
	ล้านบาท	% ของยอดรวม	ล้านบาท	% ของยอดรวม		
สินทรัพย์						
สินทรัพย์หมุนเวียน	591.52	52.26%	551.46	49.87%	40.06	7.27%
สินทรัพย์ไม่หมุนเวียน	540.35	47.74%	554.37	50.13%	(14.02)	(2.53%)
รวมสินทรัพย์	1,131.87	100.00%	1,105.83	100.00%	26.04	2.35%
หนี้สินและส่วนของผู้ถือหุ้น						
หนี้สินหมุนเวียน	337.15	29.79%	301.52	27.27%	35.63	11.82%
หนี้สินไม่หมุนเวียน	159.41	14.08%	172.17	15.57%	(12.76)	(7.41%)
รวมหนี้สิน	496.56	43.87%	473.69	42.84%	22.87	4.83%
ส่วนของผู้ถือหุ้น	635.32	56.13%	632.14	57.16%	3.18	0.50%
รวมหนี้สินและส่วนของผู้ถือหุ้น	1,131.87	100.00%	1,105.83	100.00%	26.04	2.35%

In the statement of financial position as of 31 December 2025, the Company had total assets of 1,131.87 million baht, an increase of 26.04 million Baht or 2.35% from the previous year, mainly due to an increase in current assets. Meanwhile, total liabilities amounted to 496.56 million Baht, an increase of 22.87 million Baht. The Company's capital is primarily derived from short-term loans from financial institutions and obligations related to working capital management to support the procurement of goods. Currently, the Company has credit lines of 1,037 million Baht, while shareholders' equity stands at 635.32 million Baht, a slight increase from the previous year. This is a result of the increase in net profit for the past year, after deducting dividend payments as resolved at the 2025 Company's shareholders meeting. The Company's debt-to-equity ratio as of 31 December 2025, is 0.78 times. The full financial statements are included in Form 56-1 One Report for the year 2025, Section 3, Financial Statements (pages 248-265), which has been sent to shareholders along with this meeting invitation letter. Details are provided in Attachment 1.

The Moderator then proceeded by inviting Mr. Chanat Sorakraikitikul, Chairman of the Audit Committee, to report the Audit Committee's findings to the Meeting.

Mr. Chanat Sorakraikitikul, Chairman of the Audit Committee, reported the Audit Committee's opinion to the Meeting that the Committee had reviewed and examined the Company's annual financial statements as of 31 December 2025, which have been audited and signed by Miss Atchara Suknaibaibun, Certified Public Accountant No. 4642, auditor of ANS Audit Co., Ltd. It is deemed appropriate to propose to the Board of Directors that the Company's financial statements for the year ended 31 December 2025 be submitted to the Annual General Meeting of Shareholders in 2026 for approval.

The Moderator allowed Shareholders to ask questions and express their opinions regarding the 2025 Financial Statements for the fiscal year ended 31 December 2025 through the specified channel(s). However, neither Shareholders nor proxies asked questions or expressed their opinions on this Agenda.

The Moderator, therefore, proposed that the Meeting consider and approve the Financial Statements for the year ended 31 December 2025. This agenda required the approval of the Meeting by a majority vote of Shareholders attending and casting the votes at the Meeting.

Resolution The Meeting approved the Financial Statements for the year ended 31 December 2025, as reviewed by the Audit Committee, and duly audited and certified by the Company's auditor as proposed. The resolution was passed by the majority vote of the Shareholders attending the meeting and casting their votes. The voting result was as follows:

Result	No. of votes (1 share = 1 vote)	% of Shareholders and proxies attending the meeting and casting their votes
Approved	287,839,877	100.0000
Disapproved	0	0.00
Abstained	0	-
Total	287,839,877	100.0000

Remark: There were 32 voters, totaling 287,839,877 votes

Agenda 3 To consider and approve the allocation of net profit as legal reserve fund and the distribution of dividend payment for the performance for the year 2025

(1) The Allocation of Net Profit as Legal Reserve Fund

The Chairman presented to the Meeting that in accordance with Section 116 of the Public Limited Company Act, B.E. 2535 (and amendments) (the “Public Limited Company Act”) and Clause No.45 of the Company’s Articles of Association, prescribing that “The Company shall allocate a certain amount of its annual net profit as a legal reserve fund for not less than 5 percent of its annual net profit, deducted by the accrued accumulative loss (if any) until this reserve amount is not less than 10 percent of its registered capital.”

In 2025, the Company’s net profit from the operating performance, as per separate Financial Statements for the year ended 31 December 2025, was **13,063,307.96** Baht. It was deemed appropriate to propose to the Meeting to approve the allocation of net profit from the 2025 operating performance as the legal reserve fund of **653,165.40** Baht (not less than 5% of 2025 net profit) as follows:

– Figure showing the separate Financial Statements for the year ended 31 December 2025 (B.E.2568) and 31 December 2024 (B.E.2567)

รายการ	ปี 2567	ปี 2568 (ปีที่เสนอ)
1. กุณจดทะเบียณ (บาท)	200,000,000	200,000,000
2. ทำไรสุทธิตามงบการเงินเฉพาะกิจการ (บาท)	25,827,688.36	13,063,307.96
3. หักกุณสำรองตามกฎหมาย (บาท)	1,291,384.42	653,165.40
4. ทำไรสุทธิตามงบการเงินเฉพาะกิจการ (หลังจากกุณสำรอง) (บาท)	24,536,303.94	12,410,142.56
5. กุณสำรองตามกฎหมายคิดเป็นร้อยละของทำไรสุทธิตามงบการเงินเฉพาะกิจการ	5.00%	5.00%
6. ทำไรสะสมสำรองตามกฎหมายคิดเป็นร้อยละของกุณจดทะเบียณ	8.00%	8.33%
7. ทำไรสะสมสำรองตามกฎหมายคิดเป็นมูลค่าเงินบาท	16,007,301.40	16,660,466.80

(2) The Payment of Dividend from the 2025 Operating Performance

The Chairman additionally reported to the Meeting that for the 2025 operating performance, Section 115 of the Public Limited Company Act and Clause No.44 of the Company’s Articles of Association prescribed that “The Company is strictly prohibited from paying the dividend fund from any sum other than profit. In case of the Company’s accumulative loss, dividend payment is not allowed”. In addition, the Company had a policy to pay dividend to Shareholders at the rate of not less than 40% of the remaining net profit after deduction of all kinds of reserves as regulated by law and the Company, based on net profit as per separate Financial Statements. The dividend payment might be changed, subject to the Company’s

operating plans, financial status, liquidity, business expansion plans, other necessity and appropriateness in the future.

In 2025, the Company's net profit from operating performance as per separate Financial Statements for the year ended 31 December 2025 (after reserved fund deduction) was **12,410,142.56** Baht. It was deemed appropriate to propose to the Meeting for an approval of dividend payment, based on the Company's 2025 operating performance to Shareholders at the rate of **0.0125** Baht per share in the total amount of **5,000,000.00** Baht, or equivalent to 40.29% of the remaining net profit after reserved fund deduction. The Company's dividend payout ratio conformed to the ratio outlined in its dividend payment policy. In this regard, the comparison of dividend payments from the previous year appeared as follows:

Description of Dividend Payment	2024	2025 (Proposed Year)
1. Net profit as per separate Financial Statements (after reserve fund deduction) (Baht)	24,536,303.94	12,410,142.56
2. 40% of net profit as per separate Financial Statements (after reserve fund deduction) (Baht)	9,721,714.52	4,964,057.02
3. Total amount of dividend payment (Baht)	9,900,000.00	5,000,000.00
4. Dividend per share (Baht: Share)	0.02475	0.0125
5. Dividend payment rate per remaining net profit from reserve fund deduction (%)	40.35	40.29
6. Total number of shares entitled for receipt of dividend payment (share)	400,000,000	12,410,142.56
7. Par value of share (Baht: Share)	0.50	4,964,057.02

Thereby, the Company's dividend payout ratio conformed to the ratio outlined in its dividend payment policy.

The Moderator allowed Shareholders to ask questions and express their opinions regarding the allocation of profit as legal reserve fund and the distribution of dividend payment for the 2025 operating performance. However, neither Shareholders nor proxies asked questions or expressed their opinions on this Agenda.

The Moderator, therefore, proposed that the Meeting consider and approve the allocation of profit as legal reserve fund and the distribution of dividend payment for the 2025 operating performance as proposed. This Agenda required the approval of the Meeting by a majority vote of Shareholders attending

and casting the votes at the Meeting. If the votes were to be equal, the Chairman was entitled to another casting vote.

Resolution The Meeting approved the allocation of the 2025 net profit as a legal reserve fund in the amount of 653,165.40 Baht or equivalent to 5% of the 2025 net profit. Accordingly, the total amount of legal reserve fund presently amounting to 16,660,466.80 Baht or equivalent to 8.33% of the Company's registered capital. The Meeting also approved the dividend payment for the year 2025 derived from the 2025 operating performance (separate Financial Statement) as of 31 December 2025, at the rate of 0.0125 Baht per share. In this regard, an individual Shareholder shall be deducted 10% withholding tax and entitled to a dividend tax credit at the rate of 20/80.

The Record Date determining the list of Shareholders entitled to receive the dividend payment was stipulated as 17 March 2026, and the dividend payment date was set on 25 May 2026.

The resolution was passed by a unanimous vote of the Shareholders attending the meeting and casting their votes. The voting result was as follows:

Result	No. of votes (1 share = 1 vote)	% of Shareholders and proxies attending the meeting and casting their votes
Approved	287,839,877	100.0000
Disapproved	0	0.0000
Abstained	0	-
Total	287,839,877	100.0000

Remark: There were 32 voters, totaling 287,839,877 votes.

Agenda 4 To approve the appointment of directors to replace those who retired by rotation

For this Agenda, the Chairman assigned Moderator to report the details to the Meeting.

Thereafter, the Moderator asked the Directors whose terms have expired to temporarily leave the Meeting while this Agenda was being discussed to adhere to the Good Corporate Governance Principles and to allow the Shareholders to vote freely.

Section 71 of the Public Limited Company Act B.E. 2535, and Clause No.17 of the Company's Articles of Association, prescribed that in each Annual General Meeting of Shareholders, one-third (1/3)

of the total number of directors at that moment shall be retired. In case the number of directors could not be divided by one-third (1/3), the number of retired directors shall be the closest to one-third (1/3). The directors to be retired in the first and second year after Company registration shall draw lots. For later years, the director taking the position for the longest term shall be retired.

The Board of Directors, therefore, proposed that the Meeting consider reappointing Directors whose terms have expired to serve as the Company's Directors for another term. The Shareholders could review the information about the Directors whose terms have expired and who were nominated for re-appointment in the documents sent along with the invitation letter to the Meeting.

The list of Directors to be retired by rotation were as follows;

Name	Position
1. Asst Prof Dr. Terdsak Rojsurakitti	Independent Director / Chairman of the Board of Directors / Chairman of the Good Corporate Governance and Sustainability Committee / Chairman of the Nomination and Remuneration Committee
2. Mr. Nattaphol Vimolchalao	Director / Member of the Risk Management Committee
3. Mr. Tanakorn Vidhayasirinun	Director

Primary information about the directors were as follows:

- 1. Asst Prof Dr. Terdsak Rojsurakitti** had served as an Independent Director for 6 years and 7 months. The Nomination and Remuneration Committee conducted a thorough screening and review process, considering various factors and the Company's business needs. They deemed it highly appropriate to reinstate Asst Prof Dr. Terdsak Rojsurakitti as an independent director for another term, given his expertise, medical qualifications, and ability to provide valuable advice to the Company.
- 2. Mr. Nattaphol Vimolchalao** had served as an Independent Director for 3 years. The Nomination and Remuneration Committee has carefully conducted a thorough screening and review process, considering various factors and the Company's business needs. They deemed it highly appropriate to reinstate Mr. Nattaphol Vimolchalao as an independent director for another term. This is due to his expertise in information technology and his ability to advise the Company on technology applications.

- 3. Mr. Tanakorn Vidhayasirinun** had served as a Director for 8 years and 3 months. Mr. Tanakorn is a highly qualified expert in management, possessing the knowledge and expertise to provide advice on the Company's business.

Thereafter, the Chairman proposed that the Meeting consider approving the reappointment of the 3 Directors abovenamed whose terms already expired to serve another term as these individuals have demonstrated exemplary performance throughout their terms as the Board Members, and in order to ensure the continuity of the Company's management and to maximize Shareholders' benefit.

Furthermore, in the process of selecting the Directors, the Company has provided an opportunity for Shareholders to nominate qualified candidates for election as the Company's Directors. This information was disseminated through the website of the Stock Exchange of Thailand and the Company's website, where the criteria for nominations were also outlined. The Shareholders were able to nominate individuals with appropriate qualifications for election as the Company's Directors between 3 November 2025, and 31 January 2026. However, upon the expiration of such period, there was no Shareholder nominating any candidate to be the Company's Directors.

The nomination of the aforementioned Directors has been approved in accordance with the resolution of the Nomination and Remuneration Committee Meeting No. 1/2569, held on 13 February 2026. The Board of Directors has also considered the greatest interest of the Company, as well as the abilities, qualifications, experience, and expertise, in accordance with the components of the Company's Board of Directors. The Company's Board of Directors has therefore proposed the re-appointment of the 3 individuals whose terms have expired, allowing them to serve another term as these individuals were equipped with knowledge and ability which would be beneficial and supportive to the success of the Company's business.

To adhere to the Good Corporate Governance principles, it was resolved that the 2026 Annual General Meeting of Shareholders shall re-appoint the Directors whose terms have expired, allowing them to serve another term. Individual Director nominees will be presented for Shareholders to vote on, providing Shareholders with the genuine opportunity to select Directors.

The Moderator allowed the Shareholders to ask questions and express their opinions regarding the appointment of Directors to replace those who retired by rotation. However, neither Shareholders nor proxies asked questions or expressed their opinions on this Agenda. The Moderator, therefore, proposed that the Meeting consider and approve the appointment of Directors to replace those who retired by rotation individually. This Agenda required the approval of the Meeting by a majority vote of Shareholders attending and casting votes at the Meeting.

Resolution The Meeting approved the re-appointment of each director, replacing those retired by rotation to hold the Company's director position for another term individually. The resolution was passed by majority votes of shareholders attending the meeting and casting their votes as follow:

1. Asst Prof Dr. Terdsak Rojsurakitti

Independent Director / Chairman of the Board of Directors / Chairman of the Good Corporate Governance and Sustainability Committee / Chairman of the Nomination and Remuneration Committee

Result	No. of votes (1 share = 1 vote)	% of Shareholders and proxies attending the meeting and casting their votes
Approved	287,839,877	100.0000
Disapproved	0	0.0000
Abstained	0	-
Total	287,839,877	100.0000

Remark: There were 32 voters, totaling 287,839,877 votes.

2. Mr. Nattaphol Vimolchalao

Independent Director / Member of the Nomination and Remuneration Committee

Result	No. of votes (1 share = 1 vote)	% of Shareholders and proxies attending the meeting and casting their votes
Approved	287,839,877	100.0000
Disapproved	0	0.0000
Abstained	0	-
Total	287,839,877	100.0000

Remark: There were 32 voters, totaling 287,839,877 votes.

3. Mr. Tanakorn Vidhayasirinun

Director

Result	No. of votes (1 share = 1 vote)	% of Shareholders and proxies attending the meeting and casting their votes
Approved	287,839,877	100.0000
Disapproved	0	0.0000
Abstained	0	-
Total	287,839,877	100.0000

Remark: There were 32 voters, totaling 287,839,877 votes.

The Moderator then invited the Board Members back into the Meeting room to attend the next agenda item.

Agenda 5 To approve the remuneration of the Company’s Directors for the year ended 31 December 2026

The Chairman presented to the Meeting that Section 90 of the Public Limited Company Act B.E.2535 (and amendments) and Clause No.22 of the Company’s Articles of Association prescribed that the Company’s directors are entitled to receive remunerations in form of prize reward, meeting allowance, gratuity, bonus, or other remunerations as the shareholders’ meeting consider and resolve. However, the directors' remuneration should align with the Company's performance, duties, responsibilities, and performance of each director and should be reviewed annually.

In this regard, the Nomination and Remuneration Committee Meeting No. 1/2569, held on 13 February 2026, had reviewed and determined remuneration of the Company’s Directors and sub-committee for the year 2026, considering the conformity to remuneration of the board of directors of other listed companies in industry with similar size, the Company’s operating performance, the Director’s performance and responsibilities. In addition, such amount of remuneration was within the mean based on the survey of remuneration of Thai listed companies studied by the Thai Institute of Directors (IOD) in December 2024. Therefore, it was resolved to propose to the Meeting to consider approving the determination of remuneration of the Directors for year 2026 within the budget not exceeding 800,000 Baht. Details were as follows;

Position		Meeting Allowance (Baht/Meeting/Person) ¹	
		2025	2026 (Proposed Year)
The Board of Directors	Chairman	30,000	30,000
	Directors	15,000	15,000
The Audit Committee	Chairman	20,000	20,000
	Members	15,000	15,000
Other Sub-Committees ²	Chairman	15,000	15,000
	Members	10,000	10,000

Notes

- ¹ Executive Director, consultant, employee or the representative of major shareholders are not entitled to receive the remuneration as Director or member of the sub-committees
- ² Other Sub-Committees refer to the Nomination and Remuneration Committee, the Executive Committee, the Risk Management Committee and the Good Corporate Governance and Sustainability Committee.

Subsequently, the Moderator informed the Meeting that there were Board Members who were Shareholders of the Company and had vested interests in this Agenda, namely:

(Data as of 17 March 2026)

First-Last Name	Amount of share(s)	Calculated as (%)
1. Asst Prof Dr. Terdsak Rojsurakitti	400,000	0.1%
2. Dr. Renu Ubol	380,000	0.095%
3. Mr. Nattaphol Vimolchalao	100,000	0.025%
4. Mr. Chanat Sorakraikitikul	3,000	0.000075%

Therefore, these four Board Members were considered interested parties and were not entitled to vote in this Agenda. As for the Company's Directors who served as executives and received regular salaries, they would not receive remuneration as proposed above. Hence, they were not deemed as interested parties in this Agenda.

The Moderator allowed the Shareholders to ask questions and express their opinions regarding the remuneration of the Company's Directors for the year 2026. However, neither Shareholders nor proxies asked questions or expressed their opinions on this Agenda. The Moderator, therefore, proposed that the Meeting consider and approve the remuneration of the Company's Directors for the year 2026. This Agenda required the approval of the Meeting by the votes of not less than two-thirds (2/3) of the total votes of the Shareholders presenting at the Meeting.

Resolution The Meeting approved the determination of the Board of Directors remuneration for the year ended 31 December 2026 within the budget not exceeding 800,000 Baht. The remuneration consisted of the meeting allowance and other benefits such as welfare as per the Company's regulations. The Executive Directors were excluded from this remuneration. Details of the remuneration were as follows:

The Board of Directors Remuneration for the year 2026

Position	Meeting Allowance (Baht/Meeting/Person)
The Board of Directors	
- Chairman	30,000
- Directors	15,000
The Audit Committee	
- Chairman	20,000
- Members	15,000
Other Sub-Committee	
- Chairman	15,000
- Members	10,000

The resolution of the 2026 Board of Directors remuneration was passed by a vote of not less than two-thirds (2/3) of the Shareholders attending the Meeting. The voting result was as follows:

Result	No. of votes (1 share = 1 vote)	% of Shareholders and proxies attending the meeting and casting their votes
Approved	286,956,877	100.0000
Disapproved	0	0.0000
Abstained	0	0.0000
No right to vote	883,000	-
Total	287,839,877	100.0000

Remark: There were 32 voters, totaling 287,839,877 votes.

Agenda 6 To approve the appointment of auditor and determine the audit fee for the year ended 31 December 2026

The Chairman presented to the Meeting that Section 120 of the Public Limited Company Act B.E.2535, prescribed that “The Annual General Meeting of Shareholders shall appoint the Company’s auditor and determine the audit fee each year. Previous auditor can be re-appointed.” and Clause No.36 of the Company’s Articles of Association regulated that the Annual General Meeting of Shareholders shall appoint the Company’s auditor and determine the audit fee each year.

For year 2026, the Company had proposed and inquired the fee proposal for the selection of certified public accountant and appointment of auditor of the Company and its subsidiary companies. The Audit Committee had considered based on the auditor’s operating performance, independence and remuneration, and viewed that ANS Audit Co., Ltd. of which its audit personnel were the Company’s auditors in 2025 was the auditing firm with good knowledge and understanding on the businesses of the Company group and offered reasonable audit fee. It was then considered to propose ANS Audit Co., Ltd., the certified public accountant Company as approved by the Office of the Securities and Exchange Commission to be the Company’s auditor for the year 2026.

1. Auditors’ Name

Auditor Name	CPA No.	Number of Year Providing Audit Services for the Company
1. Mr. Vichai Rujitanon	4054	-
2. Mr. Sathien Vongsanant	3495	-
3. Miss Kulthida Phasuraku	5946	-
4. Mr. Yutthapong Cheumuangphan	9445	-
5. Miss Atchara Suknaibaibun	4642	1 year
6. Miss Patcharee Sirisongsilp	9037	-

It was mandated that any of the auditors perform auditing duties and provide an auditor's opinion for the Company's Financial Statements for the year 2026. If the auditors mentioned above were unable to perform their duties, ANS Audit Co., Ltd. shall be entitled to appoint other certified auditors of ANS Audit Co., Ltd.

2. Audit Fee

Information for consideration	2025	2026 (Proposed Year)
1. Audit fee	2,070,000	2,000,000
2. Non-Audit Fee	Nil	Nil
Total	2,070,000	2,000,000

These audit fees did not include other service fees actually incurred in the course of auditing work (Non-Audit Fee), including any costs and expenses actually incurred during the provision of service (Out of Pocket Expense).

3. The relationship between the Company and those auditors

The abovenamed auditors did not have any relationship or conflict of interest with the Company, its subsidiaries, managements, major Shareholders, or any related parties. Therefore, they were independent in auditing and providing opinions on the Company's Financial Statements.

In this regard, the Audit Committee considered the criteria of the Public Limited Company Act B.E. 2535 and the Notification of the Capital Market Supervisory Board, including the qualification, eligibility of the auditor, as well as the audit fee and viewed that ANS Audit Co., Ltd. performed in accordance with the standard on auditing satisfactorily and provided useful opinions to the Company. In addition, it possessed comprehensive qualification, demonstrated a good understanding of the business of the Company group, and maintained no relationships with or vested interests in the Company, its subsidiaries, managements, major Shareholders, or related parties. Therefore, it had sufficient independence to audit and provide opinions on the Company's Financial Statements. Additionally, its audit fee was reasonable. Therefore, it is resolved to propose to the Board of Directors to propose to the 2026 Annual General Meeting of Shareholders to consider appointing the auditors and fixing the audit fee as presented above.

The Moderator then allowed the Shareholders to ask questions and express their opinions regarding the appointment of auditor and determine the audit fee for the year ended 31 December 2026. However, neither Shareholders nor proxies asked questions or expressed their opinions on this Agenda. The Moderator, therefore, proposed that the Meeting consider and approve the appointment of auditor and determine the audit fee for the year ended 31 December 2026. This agenda required the approval of the Meeting by a majority vote of the Shareholders attending and casting the votes at the Meeting.

Resolution The Meeting approved the appointment of the auditors from ANS Audit Company Limited to be the Company's auditors for the year 2026. The list of auditors was as follows

1. Mr. Vichai Ruchitanont Certified Public Accountant 4054 and/or
2. Mr. Sathien Vongsanant Certified Public Accountant 3495 and/or
3. Ms. Kultida Pasurakul Certified Public Accountant 5946 and/or
4. Mr. Yuttapong Chuamuanpan Certified Public Accountant 9445 and/or
5. Ms. Atchara Suknaibaiboon Certified Public Accountant 4642 and/or
6. Miss Patcharee Sirisongsilp Certified Public Accountant 9037

Assigned any of the auditors named above to perform the audit or review and provide an opinion on the Company's Financial Statements, including those of its subsidiaries. If the auditors named above were unable to perform their duties, ANS Audit Co., Ltd. shall assign other certified auditors of ANS Audit Co., Ltd. to act on their behalf.

The audit fee for the year 2026 was fixed at 1,750,000 Baht, and the audit fee for the subsidiaries in the amount of 250,000 Baht. The total amount equaled 2,000,000 Baht, excluding other service fees (non-audit fees) which the Company would pay as actually incurred. The resolution was passed by the majority vote of the Shareholders attending the meeting and casting their votes. The voting result was as follows:

Result	No. of votes (1 share = 1 vote)	% of Shareholders and proxies attending the meeting and casting their votes
Approved	287,839,877	100.0000
Disapproved	0	0.0000
Abstained	0	-
Total	287,839,877	100.0000

Remark: There were 32 voters, totaling 287,839,877 votes.

Agenda 7 To consider other matters (if any)

The Chairman stated that opening other agendas for Shareholders to inquire, discuss, and/or provide suggestions to the Board of Directors and/or management on matters beyond those proposed as agenda items for consideration was allowed. However, if the Shareholders wished to have other matters considered and resolved beyond those specified in the invitation letter to the Meeting, they must comply with the conditions of the law as stipulated in Section 105, Paragraph Two of the Public Limited Company Act B.E. 2535, stating "After the Meeting has considered and concluded according to the first paragraph,

shareholders holding in aggregate not less than one-third of the total number of shares sold may request that the Meeting consider other matters beyond those specified in the invitation letter to the Meeting”.

Since this Agenda pertained to other matters and the Company had no other items to propose for consideration by today’s Meeting, the Chairman then opened the floor to the Shareholders to ask questions about any other matters related to the Company.

The Moderator then gave Shareholders the opportunity to ask questions or offer further suggestions that would benefit the Company.

The Moderator informed the Meeting that there were questions from 2 Shareholders who were present in person, as follows:

Question 1 (From a shareholder attending the meeting in person, Ms. Chantharawan Charoontham)

With improved safety of Leukodepleted Pooled Platelet Concentrates (LDPPC) through Pathogen Inactivation (PI) and Single Donor Platelets (SDP) through PI, how many units are expected to be produced this year, and how many units are projected to grow annually over the next 2-3 years?

Answer by Mr. Nanthiya Darakananda, the Chief Executive Officer

Demand has grown exponentially as a result of the Thai Red Cross Society's LDPPC policy in relation to CERUS's PI, which the Company is currently working on. However, determining how many times the demand will actually translate into supply depends on several factors that the Company needs to analyze. Examples include ordering equipment, installing it in various rooms of the platelet manufacturing facility, hospitals establishing codes for dispensing this product to patients, training medical personnel who operate the CERUS system, and handling logistics and educating various medical professionals, including hematologists and other healthcare personnel. While the Company team is prepared for these things, there may be some dissatisfaction because expenses seem to have increased in recent years, especially in preparing the necessary personnel to manage this as quickly as possible. This business is expected to double in size, but it's difficult to say exactly how much. However, we see a significant increase in demand, so we ask Shareholders to continue monitoring the situation. Furthermore, we understand that the Shareholder inquiring about this is likely a person with considerable knowledge of the medical field and has probably already seen this and inquired with fellow medical professionals. We anticipate that their answers would likely reflect this as well.

Question 2 (From a shareholder attending the meeting in person, Ms. Chantharawan Charoontham)

Regarding the expansion of Mobile Blood services, how much further can we expand from the current 19 hospitals where the Company serves? What are the trends for 2026?

Answer by Mr. Nanthiya Darakananda, the Chief Executive Officer

Similar to the previous answer, the current limitations are not within the Company. Implementing Mobile Blood requires expanding the team, which may not be too difficult given the Company's preparations. However, the vehicles and equipment need to be built, permits obtained, and imported. But importantly, it's not about the supply side in terms of vehicles or personnel. The limitation lies in the process of obtaining approval from hospital administrators for this service to take place. The Company has coordinated extensively with hospitals. However, this depends on the speed and the pain points of each hospital, which are currently very numerous. We believe these numbers will double in the future, but as of today, we cannot specify how many hospitals will be added tomorrow, this month, this quarter, or this year. But I would like to encourage Shareholders to consider the trend, and those in the medical profession will see that there is a blood shortage. Because the Company can address this critical pain point, we will accelerate our expansion continuously. I believe this will enable the Company to achieve significant and sustainable growth.

Question 2 (From a shareholder attending the meeting in person, Ms. Chantharawan Charoontham)

Regarding breast cancer screening via thermograms, what was the estimated revenue from breast cancer screening last year, what are the opportunities for market expansion this year, and whether this method is already accepted as a standard screening method in Thailand?

Answer by Mr. Nanthiya Darakananda, the Chief Executive Officer

Thermogram is an innovation that has been recognized by the Ministry of Public Health through the Thai Food and Drug Administration (FDA). It is also certified by the CE Mark and meets standards in India and many other countries. In other words, it has received regulatory approval. However, it must be acknowledged that thermograms are still a relatively new innovation and are not yet the gold standard. Proving them to be a gold standard will likely take a very long time, similar to the cervical cancer screening that our Company has been working on for over 20 years, which is a cytology-first approach. In other words, the transition from vaginal or cervical swabs to molecular or HPV-first sampling has taken decades. It could be argued that the Company is in the proof-of-fact phase and treating its product or service as a startup, representing an unprecedented pattern in Thailand. The

Company started by collaborating with various local government agencies and collecting data, which it has publicly disclosed without concealment. The Company conducted tests on over 5,000 women across Thailand and found that the results were consistent with the gold standard method, which is mammograms. Although many may consider the data collected from 4-5 thousand people to be insufficient, the Company remains committed to working with government agencies, local authorities, and personnel in the provinces who are our customers, to continuously expand its reach. As more data is collected, trust will increase, especially from consumers and medical professionals. Furthermore, even medical professionals may have misconceptions today. In many presentations, many others have claimed that this test uses thermography, when in fact, thermography has been around for a long time. However, the Company's approach involves applying AI to thermography. The thermography process itself has a special protocol developed by the manufacturer, which is demonstrated by the application of AI. The Company is therefore quite confident, having already inspected over 5,000 clients, and has seen that the results are consistent with the current Gold Standard. It is thought that this screening process may take some time to gain more confidence among medical personnel. However, the main pain point is for those who have difficulty accessing the Gold Standard treatments available in Thailand, such as mammograms and/or ultrasounds, which are quite expensive. When patients are screened and diagnosed, they don't just want to know if they have cancer, but they also want to know how it can be treated and cured. The verification process, whether through mammograms or ultrasounds, still requires additional payment for a biopsy, just like a positive HPV test which requires a colposcopic examination, another with additional costs, and a subsequent biopsy. All of these expenses must be paid until the biopsy is completed to confirm the infection, only then can the treatment process, which is supported by the government, begin. Various barriers make it difficult for women to access treatment. This is something the Company is trying to address and is committed to helping with, as it has a meaningful purpose: to reduce deaths from various cancers to zero today. The Company has already seen a path forward in the field of cervical cancer, and therefore is now working on breast cancer as its second project.

Question 1 (From a shareholder attending the meeting in person, Mr. PholKrit Nampaisarn)

There are concerns about the current financial performance and share price, and we would like the Board of Directors to express their vision or explain their approach to resolving these two issues.

Answer by Mr. Nanthiya Darakananda, the Chief Executive Officer

Following up on what Mr. Rachan Arayawongchai has already explained, the first point is that the seemingly significant drop in profits last year is due to a restatement. Previously, the

Company recognized revenue immediately from the sale of a particular product, but now, due to a change in the contract structure, it is no longer recognized. The Company recognizes revenue after the test results have been verified. This means that even if the Company submits one test, it won't recognize revenue until the results are available. This restatement doesn't mean the customer won't use the service, but rather that there's a waiting period; it's known as the timing of revenue recognition. Secondly, financial performance, the simplest scenario is that if the Company decides not to invest today and maintains the same number of employees, it could potentially generate more profit than its peak year. However, this is considered short-term optimism, lasting only a year or two at best. However, because medical innovations are evolving so rapidly, if the Company doesn't prepare to embrace new technologies, innovations, and expand into new business methods, rewards that could yield results in a few years without any investment, they will eventually become a desert. Neither I nor my family, who hold over 70% of the shares, are any less hurt than those who receive lower dividends. Instead, we view it as a short-term sacrifice for long-term benefits. This applies to what I have already explained, whether it's CERUS's PI, Mobile Blood Banking, or the various innovations the Company has introduced to address the loss of women's lives from various cancers. This includes immunotherapy, which I've already described and is starting to become a trend in Thailand, as well as consumer products. Currently, the Company is involved in pet care, and if shareholders have pets, like dogs or cats, they'll understand that people love their animals as much as they love their own children. This can be considered a leap forward, a new era, and other things that the Company has developed and introduced. I hope these are the directions that I and my team have laid out to build a future of stable, rapid, and most importantly, sustainable growth.

The Moderator informed the Meeting that if there were no further questions from the Shareholders on this final Agenda, the Moderator then provided details on the Meeting's Minutes preparation process to ensure compliance with good practices. After the Meeting concluded, the Company would announce the resolutions made at the Meeting through the Stock Exchange's news dissemination system within the next business day. Additionally, the Company would prepare the Meeting's Minutes within 14 days from the Meeting Date and submit to the Stock Exchange via the Stock Exchange's information dissemination system, as well as publish on the Company's website to ensure that Shareholders would be informed of the Meeting outcome and could verify the accuracy of the Meeting.

The Moderator then informed the Meeting that all agenda items had been considered and most questions had been answered. The Moderator also offered sincere apologies for the system disruptions during the meeting, stating that the Company would work to improve and develop its services in the future.

The Chairman then expressed his sincere gratitude to all Shareholders for taking the time to attend today's Meeting and for providing invaluable feedback to the Company. He apologized for any inconvenience or errors that may have occurred during the Meeting and concluded the Meeting at 12.31 hrs.

Sign _____ *-Signature-* _____ Chairman of the Board of Directors
(Asst Prof Dr. Terdsak Rojsurakitti)

Sign _____ *-Signature-* _____ Secretary / Minutes Recorder
(Ms. Wanwisa Sroisawas)